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ABSTRACT
Objective: To evaluate the effect of metformin, cisplatin, and their combination on apoptosis of bladder cancer cells. 
Material & Methods: Urothelial cell lines 5637 were cultured until 80% confluence. Cells were exposed to metformin and 
cisplatin at certain doses for 24 and 48 hours. Cytotoxicity test was carried out by calculating the viability of bladder cancer 
cells using the MTT assay until IC  of each drug was obtained. IC  Metformin and Cisplatin obtained from the cytotoxicity 
50 50
test were used to induce apoptosis in bladder cancer cells using TUNEL assay. Additional combination doses of Metformin 
and cisplatin used to induce apoptosis were ¼ IC  (metformin + cisplatin), ½ IC  (metformin + cisplatin), and IC
50 50 50 
(metformin + cisplatin). Results: IC  of metformin was 15 uM while cisplatin was 18 uM with a 48-hour exposure. There 
50
was a difference in the mean value of the apoptosis index in all treatment groups compared to control except for the group 
exposed to IC  metformin and ¼ IC (metformin + cisplatin). Conclusion: Metformin administration solely is not able to 
50 50 
increase bladder cancer cell apoptosis. Conversely, the administration of Cisplatin can significantly increase bladder 
cancer cell apoptosis. The combination of Metformin and Cisplatin can significantly increase bladder cancer cell 
apoptosis. The rate of apoptosis in line with an increase dose of the combination of these two drugs.
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ABSTRAK
Tujuan: Mengetahui efek metformin, cisplatin, dan kombinasi keduanya dalam menginduksi apoptosis sel kaker buli. 
Bahan & Cara: Sel kanker buli (urothelial cell line 5637) dikultur hingga kepadatan 80%. Sel dipaparkan dengan 
metformin dan cisplatin dengan dosis tertentu selama 24 dan 48 jam. Uji sitotoksisitas sel dilakukan dengan menghitung 
viabilitas sel kanker buli menggunakan metode MTT assay. Data IC metformin dan cisplatin yang didapatkan dari uji 
50 
sitotoksisitas selanjutnya digunakan untuk uji apoptosis dengan metode TUNEL assay. Tambahan dosis kombinasi yang 
digunakan dalam uji apoptosis yaitu: ¼ IC  (metformin + cisplatin), ½ IC  (metformin + cisplatin), and IC  (metformin + 
50 50 50
cisplatin). Hasil: IC  metformin adalah sebesar 15 uM sedangkan IC  cisplatin sebesar 18 uM dengan waktu paparan 
50 50
selama 48 jam. Pada uji apoptosis ditemukan adanya perbedaan nilai rerata index apoptosis pada semua grup perlakuan 
dibandingkan dengan kontrol kecuali pada grup yang terpapar dengan IC  metformin dan ¼ IC  (metformin + cisplatin). 
50 50
Simpulan: Metformin dosis IC  tidak dapat meningkatkan apoptosis sel kanker buli. Sementara itu, cisplatin dosis IC  
50 50
dapat meningkatkan apoptosis sel kanker buli secara signifikan. Kombinasi metformin dan cisplatin juga dapat 
meningkatkan apoptosis sel kanker buli. Peningkatan dosis kombinasi metformin dan cisplatin sejalan dengan besaran 
apoptosis sel kanker buli. 
Kata Kunci: Metformin, cisplatin, sitotoksisitas, apoptosis. 
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COMPARISON OF BLADDER CANCER CELLS APOPTOSIS INDUCED BY 
METFORMIN, CISPLATIN, AND COMBINATION OF METFORMIN-
CISPLATIN: IN VITRO STUDY
INTRODUCTION
Bladder cancer is one of the most prevalent 
th
cancers in the urinary tract and is the 9  most 
1
malignancy of all malignancies in the world.  In men, 
th
bladder cancer is the 7  most prevalent malignancy 
with an incidence of 10.1 per 1.000.000 population, 
th
while in women it ranks 17  with an incidence of 2.5 
2,3
per 1.000.000 population.  About 2/3 of cases of 
bladder cancer are non-muscle invasive bladder 
104
Indonesian Journal of Urology, Vol. 27, No. 1, January 2020: 103 - 110
cancer (NMIBC) and about one-third of them are 
1
muscle-invasive bladder cancer (MIBC).  Currently, 
the standard treatment for bladder cancer is 
transurethral resection of bladder tumor (TURB), 
followed by intravesical instillation in the case of 
NMIBC and radical cystectomy or chemotherapy 
with radiotherapy in case of MIBC. However, the 
progression and recurrence of bladder cancer is still 
4,5
common.
Cisplatin-based chemotherapy is commonly 
used for MIBC, which is combined with other 
chemotherapeutic agents. However, the success rate 
6
of the combination chemotherapy is still low.  The 
response rate for MVAC (Methotrexate, Vinblastine, 
Adriamycin, and Cisplatin) is 46% while GC 
(Gemcitabine and Cisplatin) is 49%. The survival 
rate of MVAC and GC are 14.8 and 13.8 months 
respectively. This condition shows the lack of 
efficacy of standard chemotherapy currently 
available. In addition, the side effects of each of this 
chemotherapy are also factors need to be 
7
considered.
Metformin is one of the type II diabetes 
mellitus (DM) drug. Metformin has an ability to 
reduce the incidence and prevalence of various types 
8-11
of cancer in animal model.   Metformin is also able 
to reduce the progression and recurrence of various 
types of cancer in the animal models. In particular, 
metformin is also able to reduce the incidence of 
12,13
bladder cancer in diabetic patients.  In addition, 
metformin can also improve recurrence-free 
survival and bladder cancer-specific survival of 
diabetic patients after radical cystectomy.  At the 
cellular level, metformin is also capable of inducing 
apoptosis and decreasing bladder cancer cell 
14
proliferation.
Several studies have shown a synergistic 
effect on the combination of metformin and cisplatin 
15
in bladder cancer.  However, there is still lack of 
data on the effectiveness of the combination of the 
two drugs. Therefore, the potential of metformin as a 
therapeutic agent for bladder cancer has to be 
explored.
OBJECTIVE
To evaluate the effect of metformin, 
cisplatin, and their combination on apoptosis of 
bladder cancer cells.
MATERIAL  & METHODS
The bladder cancer cell used was cell line 
5637 obtained from the American Type Culture 
Collection (ATCC® HTB-9TM) Manassas, 
Virginia. These cells were bred in the laboratory of 
Stem Cell Research and Development Center, 
Airlangga University, Surabaya.  Cell line 5637 used 
in this research was grade II urothelial cell 
carcinoma taken from a 68-year-old Caucasian man. 
The culture medium used was RPMI 1640. It is 
needed 100 mL of RPMI 1640 media added with 
PBS 10%, penicillin-streptomycin 1% and function 
1% to make RPMI 1640 serum media.
Activation of bladder cancer cells is done by 
taking cells from the liquid nitrogen tank, then 
diluting them using a water bath at 37°C. Then, the 
cells were inserted into a centrifugation tube 
containing 10 mL of 1640 serum RPMI media and 
centrifuged at 2500 rpm for 5 minutes. The 
supernatant was removed, the precipitate formed 
was added to RPMI 1640 serum. After which the 
cells were centrifuged at a speed of 1200 rpm for 5 
minutes.  The supernatant is removed and left with 1 
mL for resuspension. The cell suspension was raised 
in TCF (Tissue Culture Flask) with growing media 
containing ​ FBS 10%. The cells were observed 
using an inverted microscope. The cells were then 
incubated in a CO2 5% incubator at 37°C with a 
loose lid.
Trypsinization was carried out to release 
cells from TCF media by adding trypsin 0.05%. The 
released cells were put into a centrifugation tube and 
RPMI 1640 was added and then centrifuged at 1200 
rpm for 10 minutes. The supernatant is removed, 
then 1 mL of media is added to cell resuspension. 
Furthermore, the cell suspension was put into a CO2 
incubator at 37°C. Cell density was calculated by 
taking a cell suspension of 20 μL, then the cell was 
calculated with the help of a hemocytometer in the 
contrast phase of the microscope. In cytotoxicity 
tests, each well requires 5.000 cells whereas for 
apoptosis tests, each well requires 250.000–300.000 
cells.
Cytotoxicity tests were carried out using 96 
microculture plates. Cells were incubated for 24 
hours in CO2 incubator at 37°C. After incubation, 
the media for each well was discarded, then replaced 
with new media containing FBS 10% and then 
treated using certain metformin doses of 1 mM, 2 
mM, 5 mM, 10 mM, and 20 mM. Besides metformin, 
cisplatin was also used with several doses, namely 1 
mM, 3 mM, 6 mM, 12 mM and 18 mM.  Micro-
cultures were then re-incubated for 24 hours and 48 
hours in CO2 incubators at 37°C.  The medium was 
removed, then each well was added with 100 μL of 
new medium and 25 μL of MTT reagent (25 μL/100 
μL per well). It was then incubated for 4 hours in 
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CO2 incubator at 37°C and added with 100 uL 
DMSO. The absorbance of the microculture plate is 
read using an ELISA reader at a wavelength of 595 
nm. The percentage of cell viability is obtained by 
the formula:
The apoptosis test consisted of five groups, 
namely one control group (without treatment) and 
five treatment groups given metformin IC , cisplatin 
50
IC , combination ¼ IC  (metformin and cisplatin), 
50 50
½ IC  (metformin and cisplatin), and IC  
50 50
(metformin and cisplatin) that obtained from 
previous cytotoxicity tests. Microplate 96 wells are 
used as a container for the growth of bladder cancer 
cells in the amount of 250.000–300.000 in each well. 
Exposure to metformin in bladder cell culture was 
carried out for 48 hours. The first apoptosis test was 
performed by the deparaffinization of the specimen 
(paraffin block) with xylene 3 times each for 3 
minutes. The specimen was then rehydrated using 
100% ethanol, 95% ethanol and 70% ethanol for 2 
minutes, 2 minutes, and 1 minute, respectively. Thus, 
the specimen was rehydrated with sterile aquabidest. 
The specimen was then dropped with 50 ml of the 
TUNEL labeling mix (consisting of 5 ml of enzyme 
terminal deoxynucleotidyl transferase and 45 uL 
fluorescein-dUTP). After that, the specimen was 
closed with siliconize cover slip.
0
The specimen was incubated at 37 C for 30 
minutes in the moist chamber, then washed with PBS 
(Phosphate Buffer Saline) 3 times. The next step was 
incubating the specimen with RNase Solution at 
0
37 C for 30 minutes. The specimen was then washed 
with PBS 3 times. The specimen with propidium 
iodide was then incubated at room temperature for 
10 minutes. Lastly, the specimen was washed with 
PBS 3 times, then covered with slide cover diameter 
of 18 mm. Observation of the apoptotic cells was 
done using a light microscope with 1000x 
magnification (green fluorescence).
RESULTS 
The viability of bladder cancer cells was 
observed using the MTT assay. Cell culture 
replication was carried out 5 times in each treatment 
group. Urothelial cell lines were cultured and 
incubated for 24 hours then observed until they 
reached a density of 50%. Then trypsinization is 
carried out to release cells from the culture plate. The 
urothelial cell subculture is done on the 96 well 
plates. Furthermore, each well is exposed to 
metformin according to the treatment dose. Cells are 
re-bred for 24 and 48 hours. The cells were then 
terminated. The cell metabolite results were read 
using the MTT assay.
The MTT results showed that the 
percentages of bladder cancer cells living with 
metformin 1 mM, 5 mM, 10 mM, and 20 mM for 24 
hours were 86.044%, 81.889%, 77.959%, 69.514% 
and 54.193% respectively (Table 1).
Additional exposure of metformin for 48 
hours showed that the percentages of bladder cancer 
cells living with metformin concentration of 1 mM,  
2 mM, 5 mM, 10 mM, and 20 mM were 69.195%, 
63.854%, 58.686%, 54.024%, and 47.163% 
respectively (Table 2).  From the analysis of the 
results of the metformin cytotoxicity test with 
exposure time of 24 and 48 hours, IC  metformin in 
50
bladder cancer cells was found to be 15 mM with   
48-hour exposure time (Figure 1).
% Cell viability   = 
 (treatment absorbance - moderate absorbance) x 100% 
     (control of cell absorbance - medium absorbance)
Table 1. Metformin cytotoxicity test at 24 hours.
No K. Med K. Sel 1 mM 2 mM 5 mM 10 mM 20 mM 
1 0.095 0.870 0.768 0.727 0.704 0.647 0.514 
2 0.096 0.879 0.770 0.734 0.696 0.626 0.510 
3 0.094 0.865 0.769 0.726 0.711 0.630 0.528 
4
 
0.096
 
0.882
 
0.776
 
0.749
 
0.708
 
0.641
 
0.525
 
5 0.098 0.866 0.737 0.723 0.687 0.634 0.506 
Total  0.478 4.362 3.820 3.659 3.506 3.178 2.583 
Mean 0.096 0.872 0.764 0.732 0.701 0.636 0.517 
% Of living cells 86.044 81.899 77.959 69.514 54.193 
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Table 2. Metformin cytotoxicity test at 48 hours.
  
  
No K. Med K. Sel 1 mM 2 mM 5 mM 10 mM 20 mM 
1 0.091 1.462 1.040 0.949 0.896 0.847 0.738 
2 0.096 1.510 1.020 0.985 0.913 0.839 0.743 
3 0.094 1.487 1.100 0.992 0.888 0.835 0.749 
4 0.093 1.465 1.050 0.967 0.915 0.851 0.757 
5 0.096 1.454 1.040 0.988 0.912 0.830 0.741 
Total  0.470 7.378 5.250 4.881 4.524 4.202 3.728 
Mean 0.094 1.476 1.050 0.976 0.905 0.840 0.746 
% Of living cell 69.195 63.854 58.686 54.024 47.163  
Figure 1. Graph of Metformin concentration on cell viability.
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Table 3. Cisplatin cytotoxicity test at 24 hours.
No K. Med K. Sel 1 uM 3 uM 6 uM 13 uM 18 uM 
1 0.095 0.870 0.784 0.732 0.697 0.654 0.631 
2 0.096 0.879 0.763 0.727 0.704 0.671 0.640 
3 0.094 0.865 0.789 0.730 0.710 0.646 0.638 
4 0.096 0.882 0.770 0.743 0.683 0.665 0.647 
5 0.098 0.866 0.774 0.738 0.713 0.679 0.644 
Total  0.478 4.362 3.880 3.670 3.507 3.315 3.200 
Mean 0.096 0.872 0.776 0.734 0.701 0.663 0.640 
% Of living cells 87.589 82.182 77.985 73.041 70.080 
 
Observation of bladder cancer cells viability 
using the MTT assay was carried out in the treatment 
group with exposure to cisplatin. There were 5 
treatment groups with cisplatin exposure dose of 1 
uM, 3 uM, 6 uM, 13 uM, and 18 uM. The percentages 
of each bladder cancer cell group living with a 24-
hour cisplatin exposure were 87.598%, 82.182%, 
77.985%, 73.041%, and 70.080% (Table 3).  
The percentages of each bladder cancer cell 
group living with a 48-hour cisplatin exposure were 
63.636%, 60.090%, 57.180%, 52.895%, and 
50.318% (Table 4).
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Table 4. Cisplatin toxicity test at 48 hours.
No K. Med K. Sel 1 uM 3 uM 6 uM 13 uM 18 uM 
1 0.095 0.870 0.784 0.732 0.697 0.654 0.631 
2 0.096 0.879 0.763 0.727 0.704 0.671 0.640 
3 0.094 0.865 0.789 0.730 0.710 0.646 0.638 
4 0.096 0.882 0.770 0.743 0.683 0.665 0.647 
5 0.098 0.866 0.774 0.738 0.713 0.679 0.644 
Total  0.478 4.362 3.880 3.670 3.507 3.315 3.200 
Mean 0.096 0.872 0.776 0.734 0.701 0.663 0.640 
% Of living cells 87.589 82.182 77.985 73.041 70.080 
 
Using the cytotoxicity test data, IC  
50
Cisplatin value was 18 uM with 48-hour exposure 
time. Apoptosis test in this study was observed using 
TUNEL Assay. This apoptosis test consists of six 
groups, namely: 1 control group (without treatment) 
and 5 treatment groups. The treatment group was 
exposed to IC  metformin, IC  cisplatin, ¼ IC  
50 50 50
(metformin + cisplatin), ½ IC  (metformin + 
50
cisplatin), and IC  (metformin + cisplatin) obtained 
50
from prior cytotoxicity tests. Observations were 
made by counting fluorescence using a light 
microscope. The means of apoptosis are 0.24, 0.34, 
3.52, 1.02, 2.72, 4.42 for control, metformin IC  (15 
50
mM), cisplatin IC  (18 uM), cisplatin ¼ IC  (4.5 
50 50
uM) + metformin ¼ IC50 (3.75 mM), cisplatin ½ 
IC50 (9 uM) + metformin ½ IC  (7.5 mM), and 
50
cisplatin IC  (18 uM) + metformin IC  (15 mM) 
50 50
group respectively (Table 5). The picture of the 
apoptosis of each group can be seen in Figure 2(A-L) 
below.  
A B
C D
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Figure 2. Apoptosis of bladder cancer cells (Urothelial cell line 5637) by TUNEL (Terminal Deoxynucleotidyl 
Transferase dUTP Nick End Labeling) Assay. Apoptotic cells are indicated with an arrow while the 
non-apoptotic cells are indicated with an arrow head. A. Control (100x magnification), B. Control 
(400x magnification), C. Metfotmin 15 mM (100x magnification), D. Metformin 15 mM (400x 
magnification), E. Metformin 3.75 mM + Cisplatin 4.5 uM (100x magnification), F. Metformin      
3.75 mM + Cisplatin 4.5 uM (400x magnification), G. Metformin 7.5 mM + Cisplatin 9 uM (100x 
magnification), H. Metformin 7.5 mM + Cisplatin 9 uM (400x magnification), I. Cisplatin 18 uM 
(100x magnification), J. Cisplatin 18 uM (400x magnification), K. Metformin 15 mM + Cisplatin     
18 uM (100x magnification), L. Metformin 15 mM + Cisplatin 18 uM (400x magnification).
 
E F
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DISCUSSION 
Bladder cancer has an increasing incidence 
2
worldwide.  Chemotherapy is usually used as 
adjuvant therapy, especially for advanced bladder 
16,17
cancer.  However, several tumor cells can become 
resistant to chemotherapy resulting in recurrence 
and/or progression to more severe cancer. For 
example, bladder cancer cells that were initially 
sensitive to cisplatin-based combination chemo-
therapy could become resistant to these chemo-
18
therapeutic agents.
Cytotoxic tests in this study using the MTT 
assay method proved that metformin was able to 
reduce bladder cancer cell proliferation (Table 1 and 
2). Decreasing proliferation of bladder cancer cells 
after exposure to metformin indicates that the 
cytotoxicity effects of metformin depend on the dose 
and duration of exposure given. Several studies have 
shown that Metformin has an anti-cancer effect and 
is effective in several types of cancer. The incidence 
of bladder cancer in patients with type II DM who 
routinely consume metformin was much lower than 
8-11,14,15,19,20
normal patients  However, there are several 
Table 5. Bladder Cancer Cell Apoptosis Test.
Group N Mean (Min-Max) p value 
Control  5 0.24 (0.129 – 0.351) 0.009*  
Metformin 15 mM 5 0.34 (0.114 – 0.565) 0.0234* 
Cisplatin 18 uM 5 3.52 (3.211 – 3.829) <0.0001* 
Cisplatin 4.5 uM + Metformin 3.75 mM 5 1.02 (0.633 – 1.407) 0.0022* 
Cisplatin 9 uM + Metformin 7.5 mM 5 2.72 (1.909 – 3.531) 0.0008* 
Cisplatin 18 uM + Metformin 15 mM 5 4.42 (3.767 – 5.073) <0.0001* 
 
Table 6. Comparison of the Apoptosis index.
Group p value 
Control vs Metformin 15 mM >0.9999 
Control vs Cisplatin 18 uM 0.0081* 
Control vs Cisplatin 4.5 uM + Metformin 3.75 mM 0.6294  
Control vs Cisplatin 9 uM + Metformin 7.5 mM 0.0428* 
Control vs Cisplatin 18 uM + Metformin 15 mM 0.0001* 
 
studies reported that metformin has a negative effect 
21
on some types of cancer.
 Cisplatin exposure to bladder cancer cells 
also has a similar effect on metformin. The greater 
and longer exposure to cisplatin, the lower the 
bladder cancer cell proliferation (Table 3 and 4). 
Furthermore, the dose of metformin needed to 
achieve 50% cell viability (IC ) is much greater than 
50
the dose of cisplatin. In this study, the IC  for 
50
metformin was 15 mM, while cisplatin was 18 uM. 
In conclusion, cisplatin is a very toxic drug for 
bladder cancer cells because only a small dose is 
needed to kill these cells, in contrast to metformin 
which is not toxic to bladder cancer cells. However, 
the in vitro dose must be tested preclinically with in 
vivo research before finally being able to proceed to 
clinical trials in humans.
This study also observed apoptosis of 
bladder cancer cells after exposure to metformin or 
cisplatin both as a single agent and a combination of 
different doses. This becomes very crucial because 
in the cytotoxicity test, it is not known whether cell 
death is induced by apoptosis or necrosis. In this 
study, it was proven that single Metformin was not 
From the normality test using Kolmogorov 
Smirnov's One sample, the data obtained from 
observation of bladder cancer cell apoptosis were not 
normally distributed (p<0.05) (Table 5). 
The next statistical analysis was done using 
the Kruskal-Wallis non-parametric test. There was a 
significant difference in the mean apoptosis index in 
each treatment group with a value of p<0.0001. 
Further analysis was carried out with Post Hoc 
Dunn's multiple comparisons test which showed a 
significant difference in the apoptosis index in each 
treatment group compared to the control group except 
in the group that received exposure to IC  Metformin 
50
and ¼ IC  (Metformin + Cisplatin) (Table 6).
50
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able to significantly increase bladder cancer cell 
apoptosis compared to control group. In contrast, 
cisplatin administration significantly improved 
bladder cancer cell apoptosis compared to control. 
The result breaks the previous theory which explains 
that Metformin can increase bladder cancer cell 
apoptosis.
The addition of combination dose of 
Metformin + Cisplatin showed a significant increase 
in the number of apoptosis, known from Post Hoc 
Analysis where the combination group Metformin + 
Cisplatin dose ¼ IC  initially did not differ 
50
significantly from the control group, to become 
significantly different when the dose was increased 
to ½ IC  and IC . The results showed a dose-related 
50 50
effect on the combination of Metformin + Cisplatin. 
However, whether the increase in apoptosis that 
occurred was caused by metformin, cisplatin, or both 
is not the focus of this study and cannot be proven 
through this study. For this reason, further research is 
needed to determine the synergistic effects and roles 
of each of these drugs.
CONCLUSION
Metformin administration solely was not 
able to increase bladder cancer cell apoptosis. 
Conversely, the administration of Cisplatin alone or 
its combination with Metformin can significantly 
increase bladder cancer cell apoptosis, while the 
apoptosis rate was higher for the combination group.
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